June 20, 2019
Syntrix doses first metastatic melanoma patient testing dual inhibotor of CXCR1/2 with Merck’s Keytruda
Syntrix Pharmaceuticals has started its Phase 1/2 clinical trial that will combine SX-682 with KEYTRUDA, Merck’s anti-PD-1 therapy, as it dosed the first patient, it said Thursday.